DK1420769T3 - Lipid profil modulation med steroider og PPAR alpha agonister - Google Patents
Lipid profil modulation med steroider og PPAR alpha agonisterInfo
- Publication number
- DK1420769T3 DK1420769T3 DK02707001T DK02707001T DK1420769T3 DK 1420769 T3 DK1420769 T3 DK 1420769T3 DK 02707001 T DK02707001 T DK 02707001T DK 02707001 T DK02707001 T DK 02707001T DK 1420769 T3 DK1420769 T3 DK 1420769T3
- Authority
- DK
- Denmark
- Prior art keywords
- steroids
- lipid profile
- ppar alpha
- alpha agonists
- profile modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0107383.2A GB0107383D0 (en) | 2001-03-23 | 2001-03-23 | Lipid profile modulation |
| PCT/GB2002/001457 WO2002076435A2 (en) | 2001-03-23 | 2002-03-25 | Lipid profile modulation with steroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1420769T3 true DK1420769T3 (da) | 2008-09-29 |
Family
ID=9911465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02707001T DK1420769T3 (da) | 2001-03-23 | 2002-03-25 | Lipid profil modulation med steroider og PPAR alpha agonister |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050032761A1 (pt) |
| EP (1) | EP1420769B1 (pt) |
| JP (1) | JP2004528308A (pt) |
| AT (1) | ATE397922T1 (pt) |
| AU (1) | AU2002241160A1 (pt) |
| CA (1) | CA2441834C (pt) |
| DE (1) | DE60227080D1 (pt) |
| DK (1) | DK1420769T3 (pt) |
| ES (1) | ES2307729T3 (pt) |
| GB (2) | GB0107383D0 (pt) |
| PT (1) | PT1420769E (pt) |
| WO (1) | WO2002076435A2 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| EP1854487A3 (en) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| CA2539741A1 (en) * | 2003-09-22 | 2005-03-31 | Bionetworks Gmbh | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| ES2369389T3 (es) | 2005-04-05 | 2011-11-30 | F. Hoffmann-La Roche Ag | 1h-pirazol-4-carboxamidas, su preparación y su empleo como inhibidores de 11-beta- hidroxiesteroide dehidrogenasa. |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| CN101312951A (zh) | 2005-11-21 | 2008-11-26 | 盐野义制药株式会社 | 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物 |
| WO2007082808A2 (en) | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-hsd1 inhibitors |
| WO2007112055A2 (en) * | 2006-03-23 | 2007-10-04 | Breyer Emilta De Guzman | Apolipoprotein fingerprinting technique |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| PL2163543T3 (pl) | 2007-05-18 | 2015-06-30 | Shionogi & Co | Heterocykliczna pochodna zawierająca azot o aktywności hamującej dehydrogenazę 11-beta-hydroksysteroidową typu I |
| CN102223797A (zh) | 2008-11-21 | 2011-10-19 | 高点制药有限责任公司 | 金刚烷基苯甲酰胺化合物 |
| US9345732B2 (en) | 2009-11-19 | 2016-05-24 | Laila Nutraceuticals | Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
| WO2012015715A1 (en) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
| US9781909B2 (en) * | 2013-07-17 | 2017-10-10 | University Of Manitoba | Mito-Ob: a transgenic mouse model for obesity |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| EP3565559A4 (en) * | 2017-01-09 | 2020-07-08 | Temple University - Of The Commonwealth System of Higher Education | METHOD AND COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS |
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| MX2021005801A (es) * | 2018-11-20 | 2021-08-05 | Sparrow Pharmaceuticals Inc | Metodos para administrar corticosteroides. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| JP2004502432A (ja) * | 2000-07-05 | 2004-01-29 | バイエル アクチェンゲゼルシャフト | ヒト１１β−ヒドロキシステロイドデヒドロゲナーゼ１様酵素の調節 |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
-
2001
- 2001-03-23 GB GBGB0107383.2A patent/GB0107383D0/en not_active Ceased
-
2002
- 2002-03-25 PT PT02707001T patent/PT1420769E/pt unknown
- 2002-03-25 CA CA2441834A patent/CA2441834C/en not_active Expired - Fee Related
- 2002-03-25 WO PCT/GB2002/001457 patent/WO2002076435A2/en active IP Right Grant
- 2002-03-25 EP EP02707001A patent/EP1420769B1/en not_active Expired - Lifetime
- 2002-03-25 GB GB0323962A patent/GB2390367B/en not_active Expired - Fee Related
- 2002-03-25 DK DK02707001T patent/DK1420769T3/da active
- 2002-03-25 ES ES02707001T patent/ES2307729T3/es not_active Expired - Lifetime
- 2002-03-25 AT AT02707001T patent/ATE397922T1/de active
- 2002-03-25 DE DE60227080T patent/DE60227080D1/de not_active Expired - Lifetime
- 2002-03-25 AU AU2002241160A patent/AU2002241160A1/en not_active Abandoned
- 2002-03-25 JP JP2002574951A patent/JP2004528308A/ja active Pending
-
2003
- 2003-09-23 US US10/668,564 patent/US20050032761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1420769E (pt) | 2008-08-05 |
| ATE397922T1 (de) | 2008-07-15 |
| JP2004528308A (ja) | 2004-09-16 |
| DE60227080D1 (de) | 2008-07-24 |
| GB0323962D0 (en) | 2003-11-19 |
| EP1420769B1 (en) | 2008-06-11 |
| CA2441834A1 (en) | 2002-10-03 |
| GB0107383D0 (en) | 2001-05-16 |
| US20050032761A1 (en) | 2005-02-10 |
| EP1420769A2 (en) | 2004-05-26 |
| WO2002076435A2 (en) | 2002-10-03 |
| GB2390367A (en) | 2004-01-07 |
| CA2441834C (en) | 2011-01-25 |
| WO2002076435A3 (en) | 2004-03-18 |
| GB2390367B (en) | 2005-04-13 |
| ES2307729T3 (es) | 2008-12-01 |
| AU2002241160A1 (en) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1420769T3 (da) | Lipid profil modulation med steroider og PPAR alpha agonister | |
| DE60217233D1 (de) | Abdichtung für Verdichter und Kreiselverdichter mit dieser Abdichtung | |
| NO20040865L (no) | Friksjon reduserende sammensetning og metode | |
| ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
| CY1112487T1 (el) | Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη | |
| DE602004019812D1 (de) | Marker für neuromyelitis optica | |
| BR0215405A (pt) | Composições e processos de uso de collajolie | |
| IS7858A (is) | Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD) | |
| CY1113651T1 (el) | Αντιφλεγμονωδη σκευασματα | |
| WO2003103571A3 (en) | VACCINES AGAINST FLAVIVIRUSES | |
| NO20044898L (no) | Nye etonogestrel estere | |
| NO20040542L (no) | Fremgangsmate for installasjon av en ankerline og kobling for bruk i fremgangsmaten | |
| NO20040055L (no) | Sarbandasje | |
| ITMI20021822A1 (it) | Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico | |
| RS51138B (sr) | S-mirtazapin za lečenje nastupa vreline (valunga) | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| PT1553942E (pt) | Composicao farmaceutica associando tenatoprazol e um anti-inflamatorio | |
| AU2003251529A8 (en) | Planetarium and point light source for the use in same | |
| NO20043107L (no) | Bronnsementeringsbestanddeler for kalde omgivelser | |
| SE0301650D0 (sv) | Novel compounds | |
| UY28531A1 (es) | Composición líquida biologicamente estable de fviii, de fww o del complejo fviii/fww humanos | |
| NO20033747D0 (no) | Fremgangsmåte ved sementering i en underjordisk sone og brönnsement til bruk ved utförelse av fremgangsmåten | |
| SE0302361D0 (sv) | Inhibering av upptagning av monoamin | |
| ITRM20050478A1 (it) | Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia. | |
| ITRM20020105A0 (it) | Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego. |